Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial.

September 24, 2026| Source: Lancet (London, England)

Gut microbiota composition might have a role in the pathogenesis of irritable bowel syndrome (IBS), and faecal microbiota transplantation has been proposed as a means of restoring healthy gut microbiota for individuals with this condition. We aimed to investigate the efficacy and safety of faecal microbiota transplantation in patients with IBS. In this parallel-group, randomised, double-blind, placebo-controlled, phase 3 trial, conducted at five hospitals in Norway, we enrolled men and women aged 18-65 years with moderate-to-severe IBS. IBS diagnosis was defined by the Rome IV criteria and an IBS-Severity Scoring System (IBS-SSS) score of 175 points or higher. A colonoscopy within 5 years before study enrolment was required for all participants aged 50 years or older to rule out colorectal cancer, and participants with IBS with predominantly diarrhoea required negative biopsies to exclude microscopic colitis. Participants were randomly assigned 2:1 to faecal microbiota transplantation with faeces samples from either healthy donors (intervention) or the participants themselves (placebo group). All investigators, participants, and study personnel involved in treatment administration, patient care, and outcome assessment were masked to treatment allocation throughout the study. Treatments were delivered as a once-only rectal enema. The primary endpoint was the proportion of participants with a reduction of 75 points or more in IBS-SSS score at 90 days after treatment compared with baseline, assessed in all patients who received their allocated treatment. All participants were advised to report any adverse event during follow-up to their study contact, preferably by telephone. A patient representative was involved in the planning of the trial. The trial was registered at ClinicalTrials.gov (NCT04691544). Between May 5, 2021, and July 14, 2022, we assessed 2304 individuals for eligibility, and 450 participants were enrolled and randomly assigned to the intervention group (299) or placebo group (151); two randomly assigned participants were excluded from analyses because their allocated treatments were switched. 293 (65%) of 448 participants were women, 155 (35%) were men, and the median age was 36 years (IQR 29-44). 119 (40%) participants in the donor faecal microbiota transplantation group and 57 (38%) in the placebo group showed an improvement of at least 75 points on the IBS-SSS at 90 days after treatment. The absolute difference was 1·9 percentage points (95% CI -8·1 to 12·0; p=0·76). The proportion of participants with adverse events was similar in the two study groups. The trial did not show a clinical benefit of faecal microbiota transplantation in patients with IBS. These findings suggest that microbiota modulation alone might be insufficient for symptom improvement in IBS. KLINBEFORSK.

Read the original source →

Related Topics

Cancer Research

Cellular remodeling during reversible life-stage transition in sessile ciliates: Genomic and transcriptomic insights.

Unraveling mechanisms driving dramatic life-stage transitions in response to environmental stress is central to understanding cellular adaptation. We studied a distinctive group of sessile ciliates that undergo profound morphological and organellar remodeling when transitioning from sessile trophonts to motile telotrochs. We generated chromosome-level genomes for two colonial species ( Campanella sinica , Epistylis hentscheli ) and one solitary species ( Vorticella campanula ), revealing genome

Selective ablation of dsDNA-specific plasma cells improves lupus nephritis in NZB/W mice.

Antibodies specific for double-stranded DNA (dsDNA) are thought to play a crucial role in the pathogenesis of lupus nephritis. Plasma cells have emerged as a promising therapeutic target in antibody-mediated diseases. Here, we show that dsDNA oligonucleotides longer than 80 bp and irrespective of their sequence, react with more than 80% of murine and human dsDNA antibodies. With a conjugate of a modified antibody to mouse CD138 and 100 bp dsDNA oligonucleotides, we demonstrate the selective depl

The genomic origins of cyanobacterial morphological diversity.

Cyanobacteria are the only prokaryotes to have evolved oxygenic photosynthesis, transforming the geochemistry and biology of the planet. They exhibit remarkable morphological diversity and represent one of the earliest known multicellular organisms, including filamentous growth and cellular differentiation. However, the genomic mechanisms underlying their repeated transitions between unicellularity and multicellularity remain unresolved. Here, we implement phylogenomic and Bayesian molecular clo

Perfluorooctane sulfonate directly interacts with IRF3 to attenuate antiviral innate immunity.

Perfluorooctane sulfonate (PFOS), a prominent per- and polyfluoroalkyl substance (PFAS), has raised significant public health concerns due to its widespread use, environmental persistence, and bioaccumulation potential. Both epidemiological and experimental studies demonstrate that PFOS exposure causes immunotoxicity and disrupts both innate and adaptive immunity. However, the specific effects of PFOS on innate antiviral immunity remain poorly understood. Here, by integrating multi-omics analysi

Sliding-before-breaking governs deformation in chitinous extracellular matrices reinforced by strong, fatigue-resistant chitin.

Many fibrous biological materials combine high strength with the ability to undergo permanent shape change, a balance that remains difficult to replicate synthetically. In twisted, plywood-like architectures, the origin of irreversible deformation remains unresolved: does strain arise from covalent bond scission or from coordinated interfacial processes across hierarchical scales? Here, we use the chitin-based protective tubes of vestimentiferan deep-sea tubeworms ( Siboglinidae: Vestimentifera